{"url_path":"/sec/odtx/8-k/2026-06-17/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1882782/0001193125-26-274291-index.html","accession_number":"0001193125-26-274291","cik":"0001882782","ticker":"ODTX","issuer_name":"Odyssey Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1882782/0001193125-26-274291-index.html","primary_entity_key":"0001882782","primary_entity_name":"Odyssey Therapeutics, Inc."},"word_count":75,"has_tables":true,"body_markdown":"## Item 9.01 Financial Statements and Exhibits.\n\nExhibit\n\nNumber\n\n \n\nDescription\n\n[99.1](odtx-ex99_1.htm)\n\n \n\nPress Release, dated June 17, 2026\n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nOdyssey Therapeutics, Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 17, 2026\n\nBy:\n\n/s/ Jason Haas\n\n \n\n \n\n \n\nJason Haas\nChief Financial Officer"}